Jennifer A. Fox - 12 Sep 2024 Form 4 Insider Report for Zenas BioPharma, Inc. (ZBIO)

Role
Chief Business Officer and Chief Financial Officer
Signature
By: /s/ Chase Jayasekera, Attorney-in-Fact
Issuer symbol
ZBIO
Transactions as of
12 Sep 2024
Net transactions value
$0
Form type
4
Filing time
16 Sep 2024, 20:48:37 UTC
Previous filing
04 Sep 2024
Next filing
18 Dec 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZBIO Stock Option (Right to Buy) Award $0 +155,000 $0.000000 155,000 12 Sep 2024 Common Stock 155,000 $17.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 25% of the underlying shares of common stock on September 12, 2025, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal month installments over 36 months thereafter, subject to continued service.

Remarks:

Chief Business Officer and Chief Financial Officer